- Report
- October 2024
- 136 Pages
North America
From €3662EUR$4,000USD£3,112GBP
- Report
- January 2019
- 144 Pages
Global
From €1259EUR$1,375USD£1,070GBP
€2517EUR$2,750USD£2,139GBP
- Report
- May 2024
- 133 Pages
Global
From €5949EUR$6,499USD£5,056GBP
- Report
- August 2022
- 118 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- March 2024
- 159 Pages
Global
From €7277EUR$7,950USD£6,185GBP
- Report
- February 2023
- 220 Pages
Global
From €6866EUR$7,500USD£5,835GBP
- Report
- February 2022
- 220 Pages
Global
From €8696EUR$9,500USD£7,391GBP
- Report
- March 2024
- 200 Pages
Global
From €3799EUR$4,150USD£3,229GBP
- Report
- October 2023
- 189 Pages
Global
From €4119EUR$4,500USD£3,501GBP
- Report
- April 2023
- 112 Pages
Global
From €4348EUR$4,750USD£3,695GBP
- Report
- May 2023
- 74 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- July 2022
- 55 Pages
Global
From €3204EUR$3,500USD£2,723GBP
- Report
- May 2022
- 86 Pages
Global
From €2289EUR$2,500USD£1,945GBP
The Angiotensin II Receptor market is a segment of the Cardiovascular Drugs market. It is composed of drugs that target the Angiotensin II Receptor, a protein found in the body that plays a role in regulating blood pressure. These drugs are used to treat hypertension, congestive heart failure, and other cardiovascular diseases. They work by blocking the action of Angiotensin II, which helps to reduce blood pressure.
The Angiotensin II Receptor market is highly competitive, with many companies offering similar products. Some of the major players in the market include Novartis, Merck, Pfizer, Sanofi, and AstraZeneca. These companies have developed a range of drugs that target the Angiotensin II Receptor, including ACE inhibitors, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors. Show Less Read more
